Amarin (AMRN)
(Delayed Data from NSDQ)
$0.69 USD
-0.01 (-1.84%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $0.69 0.00 (0.29%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Brokerage Reports
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 61 - 80 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vazkepa Potential With Global Expansion; Sights on Germany Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Timing Ripe For Vazkepa Execution; Looking to Germany Launch Expected 3Q21 to Set Tone
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Europe Can Present Second Wind for Vascepa, Despite Program?s Infancy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department